



Universiteit
Leiden
The Netherlands

Insight in modulation of inflammation in response to diclofenac intervention: a human intervention study

Erk, M.J. van; Wopereis, S.; Rubingh, C.; Vliet, T. van; Verheij, E.; Cnubben, N.H.; ... ; Ommen, B. van

Citation

Erk, M. J. van, Wopereis, S., Rubingh, C., Vliet, T. van, Verheij, E., Cnubben, N. H., ... Ommen, B. van. (2010). Insight in modulation of inflammation in response to diclofenac intervention: a human intervention study. *Bmc Medical Genomics*, 3, 5.
doi:10.1186/1755-8794-3-5

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/61749>

Note: To cite this publication please use the final published version (if applicable).

RESEARCH ARTICLE

Open Access

Insight in modulation of inflammation in response to diclofenac intervention: a human intervention study

Marjan J van Erk^{1*}, Suzan Wopereis¹, Carina Rubingh¹, Trinette van Vliet^{1,2}, Elwin Verheij¹, Nicole HP Cnubben¹, Theresa L Pedersen³, John W Newman^{3,4}, Age K Smilde^{1,5}, Jan van der Greef¹, Henk FJ Hendriks¹, Ben van Ommen¹

Abstract

Background: Chronic systemic low-grade inflammation in obese subjects is associated with health complications including cardiovascular diseases, insulin resistance and diabetes. Reducing inflammatory responses may reduce these risks. However, available markers of inflammatory status inadequately describe the complexity of metabolic responses to mild anti-inflammatory therapy.

Methods: To address this limitation, we used an integrative omics approach to characterize modulation of inflammation in overweight men during an intervention with the non-steroidal anti-inflammatory drug diclofenac. Measured parameters included 80 plasma proteins, >300 plasma metabolites (lipids, free fatty acids, oxylipids and polar compounds) and an array of peripheral blood mononuclear cells (PBMC) gene expression products. These measures were submitted to multivariate and correlation analysis and were used for construction of biological response networks.

Results: A panel of genes, proteins and metabolites, including PGE₂ and TNF-alpha, were identified that describe a diclofenac-response network (68 genes in PBMC, 1 plasma protein and 4 plasma metabolites). Novel candidate markers of inflammatory modulation included PBMC expression of annexin A1 and caspase 8, and the arachidonic acid metabolite 5,6-DHET.

Conclusion: In this study the integrated analysis of a wide range of parameters allowed the development of a network of markers responding to inflammatory modulation, thereby providing insight into the complex process of inflammation and ways to assess changes in inflammatory status associated with obesity.

Trial registration: The study is registered as NCT00221052 in clinicaltrials.gov database.

Background

In obesity, both the adipose tissue mass and the extent of macrophage infiltration increase. Moreover, both adipocytes and macrophages can release a range of inflammatory markers, thereby contributing to a local and systemic state of “low-grade” inflammation [1,2]. The systemic inflammatory status often seen in obese subjects is associated with development of obesity-related diseases like cardiovascular diseases [3,4], diabetes mellitus and insulin resistance [5-7]. Modulation of

inflammation in overweight subjects may be a means to reduce the risk of diseases associated with obesity.

However, it is difficult to detect modulation of inflammation, as inflammation is a complex process that can be poorly described with a single marker. In fact, a range of markers for local and systemic inflammation have been described and evaluated, primarily with respect to the risk of atherosclerosis and cardiovascular disease development. As with classic inflammatory conditions, obesity is associated with elevated levels of the acute phase reactant C-reactive protein (CRP) [8]. CRP is a well described marker of risk for development of both coronary heart disease [9] and type-2 diabetes [10].

* Correspondence: marjan.vanerk@tno.nl

¹TNO Quality of Life, PO Box 360, 3700 AJ Zeist, the Netherlands

Other inflammatory markers include cytokines such as interleukin-6 (IL-6), which can regulate CRP release [11,12], and tumor necrosis factor alpha (TNF-alpha), adhesion molecules such as VCAM-1, ICAM-1 and E-selectin [13] and eicosanoids like prostaglandin E2 (PGE₂) [14,15]. In type-2 diabetes, levels of multiple inflammatory markers (CRP, IL-6, adhesion molecules) are elevated in an early disease stage and increased further with disease progression [16]. Plasma sialic acid level also rises in association with metabolic syndrome, including insulin resistance and type-2 diabetes, and appears to be a marker of acute micro vesicular endothelial damage [17-19].

The focus of the present study was to investigate and provide insight into the modulation of obesity-associated inflammation, by applying a mild anti-inflammatory therapy to overweight males. Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), which is known to inhibit prostaglandin synthesis by inhibition of cyclooxygenase enzymes, was chosen as a model compound. Due to the complexity of the inflammatory process, we used a wide-range of 'omics-based' parameters to extensively characterize modulation of inflammation. This analysis approach included measurements of 80 plasma proteins, more than 300 plasma metabolite levels (lipids, free fatty acids, oxylipids and a wide array of polar compounds) and whole genome expression profiles in PBMCs.

Analysis of the 'omics-based' datasets was performed using multivariate and correlation analysis. The results were used to construct biological networks, providing visualization of the interactions between identified markers. This integrated inspection provided new insights into the complex process of inflammation and ways to assess changes in inflammatory status associated with obesity.

Methods

Subjects and study design

The study was conducted at TNO Quality of Life (Zeist, the Netherlands). Overweight or mildly obese men with a body mass index (BMI) between 25.1 and 34.0 kg/m² were recruited from a pool of volunteers. Fifty subjects gave written informed consent after being informed about the study, both verbally and in writing. All subjects completed a questionnaire on medical history and were submitted to a physical examination. Blood and urine were collected after an overnight fast for routine analysis. In addition, plasma CRP levels were determined using a high-sensitivity CRP assay.

Subjects who, based on medical histories, were not suitable to receive diclofenac treatment (history of current gastro-intestinal diseases including bleeding, ulcer or perforation, history of stroke, history of current significant hematological disorders, any significant hepatic, renal or cardiovascular disease or asthma) and subjects with allergy or hypersensitivity for non-steroidal anti-inflammatory drugs (NSAIDs) were excluded from participation. Furthermore, smokers and subjects who reported slimming or who were on a medically prescribed diet were excluded from participation. Also, subjects who were on medication that may have interfered with parameters to be measured or with diclofenac treatment and subjects with a history of medical or surgical events that may have affected the study outcomes were not included. Based on these criteria, twenty five subjects were eligible. Twenty overweight men (25 < BMI <31) were selected on the basis of the highest CRP values and nineteen completed the study. One person dropped out on the first day of the study for study unrelated reasons. Subject characteristics are presented in table 1.

Table 1 Demographic data of subjects that completed the study (n = 19) at screening.

	All (n = 19)	Placebo treatment (n = 10)	Diclofenac treatment (n = 9)
Age (years)	43 ± 15	41 ± 16 (19 - 60)	45 ± 15 (21 - 58)
Body weight (kg)	93.5 ± 8.0	93.5 ± 9.3 (81.1 - 105.2)	93.5 ± 6.9 (85.2 - 104.4)
Height (m)	1.82 ± 0.08	1.82 ± 0.10 (1.69 - 1.96)	1.83 ± 0.07 (1.70 - 1.92)
BMI (kg/m ²)	28.1 ± 1.2	28.1 ± 1.0 (26.7 - 29.3)	28.1 ± 1.5 (26.1 - 30.9)
hs-CRP (mg/L)	2.22 ± 2.33	2.08 ± 1.88 (0.41 - 6.35)	2.37 ± 2.87 (0.64 - 9.72)
Fasting glucose (mmol/L)	6.0 ± 0.5	5.9 ± 0.5 (5.2 - 7.1)	6.0 ± 0.6 (5.0 - 6.8)
Fasting insulin (mU/L)	13.4 ± 8.1	13.4 ± 8.6 (5.1 - 26.8)	13.3 ± 8.1 (3.3 - 26.6)

Values: mean ± SD (range)

The study was approved by the Medical Ethics Committee of the University Medical Centre of Utrecht (May, 2005) and conducted according to the current assembly (52nd) of the Declaration of Helsinki (Edinburgh, Scotland, October 2000) and the ICH Guideline for Good Clinical Practice (ICH Topic E6, adopted 01-05-1996 and implemented 17-01-1997). The study is registered as NCT00221052 in clinicaltrials.gov database.

The study was designed as a double blind, randomized, parallel trial, in which subjects were treated with diclofenac ($n = 9$) or placebo ($n = 10$). Randomization of subjects to treatment groups was restricted by CRP, BMI, fasting glucose and age. Subjects consumed one capsule (placebo or 50 mg diclofenac) approximately one hour before breakfast, lunch and dinner for 9 days. A treatment period of 9 days was chosen as suitable treatment duration to both detect anti-inflammatory effect and avoid side effects as much as possible. The dose of 150 mg/day is a common dose prescribed in osteoarthritis or rheumatoid arthritis (e.g. [20]).

Subjects were instructed to keep their habitual diet during the study. Blood samples were taken after an overnight fast on day 0, 2, 4, 7, 9 and 10. Subjects underwent an oral glucose tolerance test (OGTT) on day 0 and day 9 (data discussed in [21]).

Measurement of PGE₂, CRP and sialic acid levels

Levels of PGE₂, hsCRP and sialic acid were measured in fasting plasma. PGE₂ was determined using the Prostaglandin E₂(¹²⁵I) Biotrak assay system (Amersham Biosciences, UK) with modifications. In short, PGE₂ in samples was derivatized to the methyl oximate derivative. The resulting solution was further diluted (final dilution 5 times) in PBS and assayed. The assay consists of incubation of the oximated sample PGE₂, the ¹²⁵I-labelled PGE₂, and a PGE₂ specific antibody. After incubation, the Amerlex-M reagent is added and the free and bound ¹²⁵I labeled PGE₂ separated using centrifugation. The resulting bound radioactivity in the pellet is determined using a gamma-counter. One subject (number 7) was excluded from the PGE₂ analysis since day 0 value was missing due to an analytical problem.

CRP levels were determined using the CRP ELISA kit 'CRP sensitiv' (Immun Diagnostik, Bensheim, Germany) according to the manufacturer's instructions. The enzymatic determination of sialic acid (N-acetyl-neuraminic acid) was performed using the colorimetric assay by Roche Diagnostics (Mannheim, Germany).

Data were analyzed for time and treatment effects using 2-way ANOVA in SAS v9 (SAS Institute Inc., Cary, USA).

RNA isolation, labeling and hybridization

Peripheral blood mononuclear cells (PBMCs) were isolated from fasting blood samples taken on day 0 and day 10. Blood was transferred to Leucosep tubes filled with Fycoll and centrifuged at $800 \times g$ for 20 min. Then, the PBMC layer was transferred to a clean tube and after two steps of washing with PBS and centrifugation at $225 \times g$ for 10 min, PBMCs were resuspended and stored at -70°C . RNA was isolated from PBMCs using NucleoSpin columns (Bioké, Leiden, the Netherlands) according to the manufacturer's instructions. Integrity of RNA obtained was examined by Agilent Lab-on-a-chip technology using the RNA 6000 Nano LabChip kit and a bioanalyzer 2100 (Agilent Technologies, Amstelveen, the Netherlands).

The isolated RNA samples were sent to ServiceXS BV (Leiden, the Netherlands) where they were processed according to Affymetrix protocols. In brief, RNA concentration was determined by absorbency at 260 nm, and quality and integrity was verified using the RNA 6000 Nano assay on the Agilent 2100 Bioanalyzer (Agilent Technologies).

Next, 2 μg of high quality total RNA was used with the Affymetrix Eukaryotic One-Cycle Target Labeling and Control reagents to generate biotin-labeled anti-sense cRNA. The quality of the cRNA was checked using the Agilent 2100 bioanalyzer. The labeled cRNA was further used for the hybridization to Affymetrix Human Expression U133 2.0 Genechips (with 54613 probesets). After an automated process of washing and staining, absolute values of expression were calculated from the scanned array using the Affymetrix GCOS software.

Transcriptome data analysis

Quality control and normalization of microarray data was performed using R/BioConductor packages through the NuGO MadMax pipeline <https://madmax.bioinformatics.nl>, which is also available as a Genepattern procedure on <http://nbx2.nugo.org>[22]. One array did not pass the quality control, due to high background values and the data for this subject from the diclofenac group was excluded from the transcriptome data analysis.

Raw signal intensities from CEL files were normalized using the GCRMA algorithm. Normalized signal intensities below 10 were replaced by 10 and only probesets with at least one signal intensity value >15 were included in further data analysis (24833 probesets). Data were log (base2) transformed and a 2-way ANOVA was performed using SAS v9 (SAS Institute Inc., Cary, USA) to assess the time \times treatment interaction effects. To reduce number of genes in the multivariate analysis and thus the skewness of the dataset, genes with $p < 0.1$ for time \times treatment interaction in the ANOVA (3355

genes) were selected and analyzed further using PLS-DA using Matlab Version 7.0.4 R14 (The Mathworks, Inc.) as described below under *Multivariate analysis of 'omics' data*.

Subsets of genes selected by PLS-DA were analyzed in GenMAPP v2.0 <http://www.genmapp.org> to find functional groups of genes (based on Gene Ontology) that were overrepresented in these subsets [23]. Transcriptome data are available through ArrayExpress (E-TABM-740).

Proteomics analysis

Blood collected in the presence of EDTA provided plasma samples, which were shipped to Rules Based Medicine, Inc. (Austin, USA). Measurement of expression levels of 79 proteins (HumanMAP, antigen panel) was conducted using fully automated, bead-based multiplex sandwich immunofluorescence assays (see list of proteins in additional file 1).

Some of the variables in the proteomic data set contained a high number of measurements below the detection limit which could seriously disturb the statistical analysis. Therefore, the so-called 80% rule [24] was applied to retain only those peaks which have 80% or more values above the detection limit for at least one of the two treatment groups, resulting in retention of 64 out of the 79 variables. Although they did not fulfill the criteria of the 80%-rule, TNF-alpha (65% and 67% of values above detection limit in placebo group and diclofenac group, respectively) and matrix metalloproteinase 9 (MMP-9) (65% and 78% of values above detection limit in placebo group and diclofenac group, respectively) were also retained due to their known role in inflammation, resulting in 66 proteomic variables being included for statistical analysis. Values below the detection limit that remained in the truncated data set were replaced by a value of half of the lower assay limit.

Metabolomics analysis

The analysis of plasma samples for lipids, free fatty acids (FFA) and "polar" metabolites by liquid chromatography-mass spectroscopy (LC-MS) and "global" metabolite assessments by GC-MS and preprocessing of the metabolic profiling data are described in detail by Wopereis et al. [21]. The LC-MS FFA data set contained 14 annotated peaks, the LC-MS Lipids data set consisted of 61 annotated peaks, 120 metabolites were included in the LC-MS polar data set and the GC-MS global data set contained 137 metabolites.

Oxylipids analysis

The oxygenation of polyunsaturated fatty acids yields a wide variety of compounds with potent inflammatory and anti-inflammatory properties (e.g. prostaglandins).

In this study, plasma oxylipids were quantified using modification of published procedures [25]. Specifically, samples were randomized and extracted using 60 mg Oasis HLB (Waters Corporation, Milford, MA) solid phase extraction (SPE) cartridges along with a laboratory plasma reference material, a supplied replicate sample and a blank of pH 7.4, 0.1 M phosphate buffered saline solution (PBS). SPE cartridges were pre-washed then conditioned with 3.5 mL with 0.1% acetic acid in 5% methanolic water. Samples and controls (250 µL) were placed in independent SPE solvent reservoirs, then spiked with deuterated analytical surrogates and an antioxidant/chelator mix (EDTA and butylated hydroxy toluene), then allowed to equilibrate for 2 min. Samples were diluted with 1 mL of 0.1% acetic acid:5% MeOH solution, drawn through SPE cartridges by light vacuum, washed with 3.5 mL 0.1% acetic acid:5% MeOH solution and sorbent was dried under 20 psi vacuum. Analytes of interest were eluted with MeOH followed by ethyl acetate into polypropylene tubes containing 2 µL glycerol. Solvents were removed under vacuum and residues stored at -20°C until day of analysis. Upon analysis residues were reconstituted with 50 µL of 800 nM 1-cyclohexyl-ureido-3-dodecanoic acid (CUDA) in MeOH and filtered with Durapore® PVDF 0.1 mm spin-filter tubes (Millipore, Billerica, MA, USA), at 4°C, then transferred to autosampler vials.

Analytes from sample extracts (10 µL) were separated by reverse phase gradient (A: H₂O w/0.1% acetic acid and B: 90:10 acetonitrile/isopropanol (v/v) at 250 µL/min) on a UPLC using a 2.1 × 150 mm HSS-C18 Acquity column (Waters Corp.). Oxylipids and fatty acids were detected by negative mode electrospray ionization on a Quattro Micro (Waters Corp.) tandem mass spectrometer. Analytes were quantified with QuanLynx v.4.0 software (Waters) using internal standard methodologies against a minimum 5 pt calibration curve bracketing all reported concentrations.

Multivariate analysis of 'omics' data

Partial Least Squares Discriminant analysis (PLS-DA; [26]) was used to identify genes, proteins and metabolites that differed in their change between day 0 and day 9 between the diclofenac and placebo group. Data were mean-centered for analysis. In PLS-DA, a Y-variable containing class membership information is correlated to a data matrix (X-block). The subjects who received the placebo and diclofenac treatments were assigned to class '0' and class '1', respectively. The X-block was defined for each data set (genes, proteins and metabolites per platform) by subtracting the day 0 values from the day 9 values, and a PLS-DA model was made for each data set. The largest number of PLS factors that was considered was 10.

The PLS-DA models were evaluated using a 'leave-one-out' cross-validation scheme [27], such that data from one subject was left out in the first cross-validation step, a PLS-DA model was built, and the treatment class membership of removed subject was predicted. The process was repeated until all 19 subjects were left out once. The error rate of the model was determined by comparing the original class membership and the predicted one. The optimal number of latent variables (LVs) was determined based on the minimum value of this error rate and the final fit of the model was made using this number of optimal LVs.

PLS-DA models with error rates below 30% were optimized by performing variable selection based on a jack-knife approach. In this procedure, data of one subject was left out and a PLS-DA model was made using the same number of LVs that was used for the final model. This was repeated until all 19 subjects were left out once, resulting in 19 sets of regression coefficients, the standard deviation of which was used to determine the relative standard deviations (RSDs) of each regression coefficient. Only those variables with RSDs <50% were included in a truncated data set used to build a second PLS-DA model. Components that contributed to treatment differences were identified based on the absolute regression coefficients of this model. All multivariate data analyses were performed using Matlab Version 7.0.4 R14 (The Mathworks, Inc.).

(Combined) data analysis & interpretation

Differences between response to diclofenac and placebo treatment was analyzed by PLS-DA (as described above) and 2-way ANOVA. Markers which increased or decreased at least 20% in 6 or more subjects in the diclofenac group were considered specifically responsive to diclofenac intervention. Markers that showed a >20% change in the same direction in 6 or more subjects in the placebo group were disregarded. The changes in selected markers are displayed as a heatmap.

Correlation analysis was performed in SAS Enterprise Guide v. 4.1 (SAS Institute Inc., Cary, USA). The significance threshold was set to $p < 0.01$. Biological networks were generated using curated interactions in MetaCore v4.7 (GeneGo Inc., St. Joseph, MI, USA). MetaCore™ is based on a proprietary manually curated database of human protein-protein, protein-DNA and protein compound interactions, metabolic and signaling pathways and the effects of bioactive molecules in gene expression. Lists of genes, proteins and metabolites that responded to diclofenac and lists of genes, proteins and metabolites with highest correlation to CRP changes were uploaded into MetaCore™ for construction of biological networks based on known interactions. Pathway

maps were edited in Mapeditor (GeneGo Inc., St. Joseph, MI, USA) version 2.6.0.

Results

Inflammatory markers

In the current study modulation of inflammation by diclofenac was investigated by integrated analysis of the response of genes in peripheral blood mononuclear cells (PBMC) and of proteins and metabolites in plasma, including known inflammatory markers, in order to investigate modulation of inflammatory status in state of obesity.

Firstly, effects of diclofenac on known inflammatory markers CRP, PGE₂ and sialic acid were assessed. While sialic acid levels were not different between groups, responses of PGE₂ and CRP on diclofenac treatment differed significantly from responses on placebo treatment (PGE₂: treatment × time interaction $p = 0.017$; hsCRP: treatment × time interaction $p = 0.0273$).

As expected, diclofenac treatment decreased PGE₂ levels (48.9 ± 10.6 pg/mL (mean ± stdev) at day 9 compared to 55.3 ± 11.9 pg/mL at day0, $p = 0.047$), as displayed in figure 1. In contrast, CRP levels were significantly reduced in the placebo group (2.05 ± 2.30 µg/mL (mean ± stdev) at day 9 compared to 4.03 ± 3.34 µg/mL at day0, $p = 0.0062$), but not in the diclofenac group. As illustrated in figure 2, four subjects in the placebo group exhibited elevated CRP levels (>5 µg/mL) at day 0. The CRP levels in three of these subjects dropped below 2 µg/mL at day 9, resulting in a 3.6 to 8 fold reduction in CRP levels at day 9 compared to day 0.

Combined analysis of diclofenac treatment effects

In addition to assessment of classical markers, changes in PBMC transcriptome, plasma proteome and plasma metabolome were assessed. Transcriptomic, proteomic and metabolomic datasets were submitted to supervised multivariate analysis (PLS-DA) to identify differences in response to diclofenac treatment compared to placebo. The results of the analysis are shown in table 2. With respect to metabolomic datasets, a significant difference between diclofenac and placebo treatment was detected only for metabolites from the oxylipid metabolomics platform: a set of 19 oxylipids were retained in a model with 10.5% error rate (see additional file 2). More detailed analysis of metabolomics data showed that, for other metabolomics platforms (GC-MS global, LC-MS polar, LC-MS lipids and LC-MS free fatty acids) changes were only detected in combination with an oral glucose tolerance test [21]. In addition to oxylipids, plasma protein and PBMC gene expression data also indicated differential signatures between diclofenac and placebo groups. The selection of 46 plasma proteins is listed in additional file 3. The selection of 3355 genes was




Figure 1 PGE2 levels before (day0) and after (day9) supplementation with placebo and diclofenac. The PGE2 response was significantly different for diclofenac compared to placebo (ANOVA, treatment * time interaction $P < 0.05$). In the diclofenac group, the difference in PGE2 level between day 9 and day 0 was significant (p-value = 0.0469).




Figure 2 CRP levels before (day0) and after (day9) supplementation with placebo and diclofenac. The CRP response was significantly different for diclofenac compared to placebo (ANOVA, treatment * time interaction $P < 0.05$). In the placebo group, hsCRP levels were significantly different at day 9 compared to day 0 ($P = 0.0062$).

submitted to enrichment analysis, to assess which biological processes are involved in the differential response between diclofenac and placebo intervention. Almost all top-ranked processes were inflammation-related, such as defense response, immune response, inflammatory response and response to stress (see additional file 4 for a complete list of enriched biological processes). A primary goal of this study was to identify markers for modulation of inflammation in response to diclofenac

intervention. The inflammatory modulation by diclofenac was investigated by detailed analysis of responses of genes, proteins and oxylipids selected by multivariate analysis. Markers that respond specifically to diclofenac intervention were selected based on >20% increase or >20% decrease in at least 6 subjects treated with diclofenac (as described above in *(Combined) data analysis & interpretation*). To focus on modulation of inflammation by diclofenac, and not acute phase response, only

Table 2 Overview of results of multivariate analysis (PLS-DA) of various data sets.

	Original data set		After variable selection	
	# variables	error rate	# variables	error rate
plasma proteomics	66	21%	46	10%
plasma oxylipids	30	26%	19	10.5%
plasma GC-MS	137	42%	-	-
plasma LC-MS polar	130	53%	-	-
plasma LC-MS lipids	61	37%	-	-
plasma LC-MS free fatty acids	14	37%	-	-
PBMC transcriptomics	-	-	3355	0%

All data sets were analyzed for differences between diclofenac and placebo treatment by PLS-DA. The results of the different multivariate models are expressed as error rates. Only when the error rate for the original data set was $\leq 30\%$, analysis was continued by variable selection, as described in the materials and methods section.

markers that did not show significant correlation to CRP response (across all subjects) were selected. This resulted in the selection of 68 genes, 1 protein and 3 oxylipids. The expression changes of these markers are visualized in a heatmap (Figure 3), together with changes in PGE₂. In addition to changes in PGE₂, diclofenac intervention also altered levels of other plasma oxylipids, increasing 5,6-dihydroxy-eicosatrienoic acid (5,6-DHET) and 20-HETE (20-hydroxyeicosatetraenoic acid) and decreasing the linoleate derived 9,10-dihydroxyoctadecenoic acid (9,10-DHOME). The arachidonic acid metabolite 5,6-DHET is a stable hydrolysis product of the 5(6)-epoxyeicosatrienoic acid (5(6)-EET) (not measured in current study) which itself is a substrate of cyclooxygenase leading to formation of epoxy prostaglandins. Levels of arachidonic acid (measured in FFA metabolomics analysis) were increased in the diclofenac group at day 9 compared to day 0, but the responses in diclofenac and placebo treatment groups were not significantly different (data not shown). Diclofenac intervention resulted in decreased levels of TNF-alpha. Furthermore, the selection of genes includes genes with a known role in inflammation like T cell receptor alpha (TRA@), but also genes with unknown function. The network in figure 4 summarizes and visualizes the effect of diclofenac on inflammation: inhibition of prostaglandin synthesis and changes in associated oxylipids, together with inhibition of TNF-alpha and closely related genes and proteins like caspase 8.

Discussion

Obesity is often associated with elevated indicators of a chronic inflammatory state. However, many common inflammation markers report on different aspects of this condition, highlighting that inflammation is complex

and multifactorial. In this study of moderately overweight subjects, we investigated the impact of a 9-day standard dose of the NSAID diclofenac on a broad array of transcriptomic, proteomic and metabolomic markers, including many common markers of inflammatory status. A recognized mechanism of NSAID antipyretic, analgesic and anti-inflammatory efficacy is through the blockade of prostaglandin synthesis by inhibition of cyclooxygenase enzymes. Consistent with this mechanism, a reduction in plasma PGE₂ levels was observed in the diclofenac treatment group. Additionally, diclofenac intervention resulted in reduced levels of inflammation marker TNF-alpha.

Established inflammatory markers are mostly associated with obesity-related diseases like cardiovascular disease and type-2 diabetes [9,13,16]. The subjects in the current study were overweight and relatively healthy, i.e. before manifestation of obesity-related diseases. The lack of response of most of these inflammatory markers other than PGE₂ to modulation of inflammation by diclofenac and the interference of acute phase response markers in the placebo group clearly demonstrates the need for more detailed and accurate descriptors of low-grade inflammatory status and its modulation, specifically associated with mild obesity. This study identified a panel of genes, proteins and metabolites that describe a diclofenac-response network in overweight subjects. This panel contains potentially more stable and sensitive markers of modulation of low-grade inflammation in overweight subjects, as compared to the established markers that often also respond to an acute inflammatory challenge. As indicated in figure 4, many of these novel markers appear functionally related to the accepted mode of action of diclofenac. Inhibition of prostaglandin synthesis results in higher levels of arachidonic acid and its oxylipid metabolites 5,6-DHET and 20-HETE. The intermediate metabolite 5(6)-epoxy eicosatrienoic acid (5(6)-EET) is a potent modulator of ion conductance in various tissues, and its biological effects are often COX-dependent [28-30]. While no change in PBMC COX-2 expression was detected, annexin A1 (ANXA1) expression was induced in response to diclofenac, increasing $64 \pm 41\%$ (mean \pm stdev) in this cell type. This anti-inflammatory protein can inhibit enzymes phospholipase A2 and COX-2, thereby inhibiting prostaglandin synthesis [31]. TNF alpha can also affect prostaglandin synthesis by inducing expression of prostaglandin synthase [32]. Network analysis identified diclofenac responsive genes T cell receptor alpha, caspase 8 and AKAP13 as markers functionally related to TNF alpha, as shown in figure 4. It is known that NSAID, including diclofenac, can suppress TNF alpha induced NFkB activation [33] and that NFkB can regulate prostaglandin synthesis through COX-2 [34]. The

identifier	name	2	3	4	7	8	15	16	17	19	legend
244357_at	---	17.1	30.7	32.3	166.7	220.8	0.3	NA	29.7	90.7	>100%
233011_at	ANXA1	101.4	45.8	99.3	37.3	6.2	125.0	NA	36.0	59.5	>50%
228250_at	FNIP1	-8.5	43.6	-3.3	105.9	199.4	47.4	NA	28.2	123.7	>20%
236620_at	RIF1	-5.2	48.5	7.7	71.7	149.1	46.4	NA	62.7	102.8	between -20% and 20%
235701_at	---	-2.1	60.4	30.5	280.9	84.9	75.2	NA	-22.3	47.7	<-20%
_20_HETE (M)	---	57.9	42.5	31.8	56.7	-50.0	57.9	161.5	-16.1	312.5	<-50%
224567_x_at	MALAT1	-38.0	28.5	11.7	177.9	119.9	76.2	NA	43.0	84.7	<-100%
1562364_at	---	42.1	-23.1	20.3	25.2	75.4	98.4	NA	167.7	72.2	
227062_at	NCRNA00084	26.1	24.6	24.3	176.6	101.0	3.1	NA	3.0	136.0	
222909_s_at	BAG4	67.9	20.2	220.0	78.0	41.8	26.9	NA	2.0	27.7	
207067_s_at	HDC	67.6	0.0	0.0	38.3	73.5	55.1	NA	38.5	179.2	
1555261_at	---	72.6	41.9	-2.3	73.2	72.3	21.6	NA	48.4	73.2	
233960_s_at	LOC115110	64.8	26.4	111.2	-13.4	64.0	4.4	NA	133.5	42.0	
233819_s_at	RNF160	61.3	39.5	-34.5	111.4	102.0	100.3	NA	27.6	18.4	
241155_at	---	15.7	45.0	59.0	155.4	52.7	8.9	NA	22.3	48.8	
1556750_at	LOC153577	36.5	37.1	24.2	124.3	67.6	38.1	NA	48.1	9.9	
1555439_at	GTF3C3	-14.6	37.2	12.3	68.2	40.1	58.4	NA	66.3	95.3	
1569512_at	---	18.7	11.3	27.3	48.8	116.4	74.1	NA	25.4	36.4	
1559426_at	---	31.5	-6.2	-2.1	64.2	54.3	38.1	NA	73.2	102.0	
1555058_a_at	LPGAT1	-33.5	62.1	25.3	34.3	122.0	38.3	NA	3.0	110.7	
213957_s_at	CEP350	56.0	19.3	73.6	27.7	76.4	-1.5	NA	32.3	38.9	
227039_at	AKAP13	30.4	31.5	36.0	100.3	79.9	-21.0	NA	6.4	72.6	
244389_at	TLK1	41.4	20.9	52.5	40.3	27.0	20.0	NA	22.6	84.5	
232890_at	---	27.9	21.0	26.5	135.9	78.0	4.5	NA	3.0	40.9	
209203_s_at	BICD2	20.9	57.7	33.5	26.8	103.1	-5.9	NA	11.2	80.7	
1559479_at	PI4K2B	22.1	25.8	-19.4	53.5	53.4	67.1	NA	45.7	65.5	
1554154_at	GDAP2	0.1	51.2	21.9	99.9	49.4	4.6	NA	29.4	62.4	
215635_at	---	12.4	0.4	33.8	66.9	55.3	61.6	NA	35.1	33.1	
_5_6_DHET (M)	---	50.0	55.0	-20.8	52.6	4.5	16.1	62.5	42.1	83.3	
225369_at	ESAM	60.0	28.9	-2.7	-8.9	82.7	31.2	NA	28.7	80.3	
1560492_at	---	43.9	13.5	35.6	52.5	17.3	43.6	NA	41.0	27.7	
1558938_at	---	36.1	58.0	5.9	44.0	33.4	42.8	NA	14.2	35.9	
220578_at	ADAMTSL4	22.8	27.9	21.2	40.9	-3.9	8.6	NA	58.4	105.0	
232248_at	PCSK7	-21.0	96.5	104.8	35.4	28.4	64.5	NA	32.4	-41.0	
238831_at	TMEM33	47.3	32.9	20.8	14.1	61.7	-7.4	NA	37.7	55.7	
227882_at	FKRP	25.6	-12.7	41.3	-15.2	27.5	135.0	NA	31.2	62.2	
218533_s_at	UCKL1	40.4	39.0	41.1	29.7	24.0	38.0	NA	10.8	8.1	
230014_at	---	37.6	49.0	-23.0	37.4	42.5	16.4	NA	30.1	38.2	
213530_at	RAB3GAP1	-10.7	-3.0	34.1	22.1	34.2	74.5	NA	22.7	62.1	
213328_at	NEK1	-16.3	28.6	29.2	73.7	41.7	38.8	NA	-4.7	25.2	
1558561_at	HM13	21.4	34.8	27.7	59.9	23.0	4.9	NA	-2.2	34.9	
1569276_at	---	43.3	7.0	29.7	30.4	49.8	29.9	NA	-27.0	42.7	
226436_at	RASSF4	21.1	-26.9	25.6	54.9	36.7	46.5	NA	12.3	33.4	
229544_at	---	40.5	52.7	-1.8	20.0	25.7	3.2	NA	35.8	23.0	
217983_s_at	RNASET2	22.8	3.4	28.9	27.0	19.2	27.8	NA	22.9	20.6	
53987_at	RANBP10	45.9	36.6	25.7	21.6	-8.5	33.9	NA	25.5	-0.6	
229982_at	QSER1	25.9	31.3	-13.7	26.1	46.8	-3.8	NA	25.2	40.5	
PGE2 (M)	---	-16.8	1.4	-21.4	NA	-4.7	14.2	-19.0	-30.7	-5.9	
1566446_at	---	-47.1	-25.0	-44.3	15.4	-45.7	14.0	NA	-20.1	-27.8	
218735_s_at	ZNF544	-6.1	-35.8	-24.9	-29.4	-25.6	-26.4	NA	0.4	-27.6	
230298_at	LOC153364	12.3	-29.9	6.6	-47.9	-24.5	-29.3	NA	-34.4	-37.5	
222056_s_at	FAHD2A	-24.1	-25.6	-30.8	-20.2	-23.8	0.1	NA	-35.3	-42.0	
227768_at	ZNF407	-16.1	-21.3	-29.1	-28.0	-7.7	-33.2	NA	-20.9	-51.3	
225723_at	C6orf129	-47.5	-42.2	-38.7	2.0	-25.5	-9.1	NA	-27.3	-33.6	
207686_s_at	CASP8	-14.4	-44.6	-24.5	-21.0	-28.4	-14.1	NA	-29.2	-45.7	
226287_at	CCDC34	-47.2	6.1	-20.8	12.0	-48.7	-28.5	NA	-35.2	-79.8	
224140_at	NPCDR1	-53.6	-22.0	-28.4	-32.4	-66.6	-25.9	NA	-7.7	-4.0	
244033_at	C14orf145	2.4	-25.0	0.0	-32.4	-84.7	-48.1	NA	-26.1	-34.7	
211685_s_at	NCALD	-1.4	-75.2	-23.5	3.1	-41.6	-24.4	NA	-26.7	-58.9	
223542_at	ANKRD32	-27.4	-6.4	-81.3	-21.0	-61.1	-26.7	NA	8.4	-47.0	
1553176_at	SH2D1B	-53.6	-65.2	-21.4	-51.8	-68.3	56.4	NA	-13.0	-64.3	
228469_at	PPID	-66.9	-31.0	-88.5	-51.8	-23.0	12.7	NA	-2.9	-39.4	
229070_at	C6orf105	-55.0	-27.3	-133.1	-50.8	-54.3	13.1	NA	4.4	-27.5	
227356_at	---	-14.3	-77.8	-70.1	-40.7	-29.4	-39.4	NA	-11.7	-21.4	
218503_at	KIAA1797	-28.5	-66.2	-83.1	-67.1	-37.0	-30.9	NA	-16.6	4.8	
209686_at	S100B	-75.8	-116.7	-65.4	-23.6	-45.8	-24.5	NA	0.0	0.0	
234013_at	TRA@	-44.4	-69.7	-100.3	-80.6	-65.7	9.3	NA	3.6	-27.6	
207376_at	VENTX	-55.1	-74.9	-2.3	-29.4	-14.6	-38.7	NA	-74.3	-88.0	
242560_at	FANCD2	-57.0	-84.9	-153.3	-28.7	-50.8	-44.9	NA	-12.2	11.1	
_9_10_DHOME (M)	---	-40.1	3.3	-205.3	-31.7	-41.9	-476.4	6.7	-38.2	79.8	
210733_at	TRAM1	-4.9	-39.8	-37.9	-182.8	-85.8	-37.7	NA	-9.8	-37.6	
223577_x_at	MALAT1	-48.9	-36.8	-87.9	-29.8	-65.5	-206.6	NA	-10.0	23.6	
TNF (P)	---	-170.8	7.7	-238.5	-306.2	0.0	-238.5	-238.5	-25.0	438.5	

Figure 3 Heatmap of responses of 68 genes, 1 protein (P) and 4 metabolites (M) to diclofenac intervention. Numbers represent % change in each subject in response to diclofenac. Each row lists identifier and name. For genes identifiers are Affymetrix probeset IDs, for proteins and metabolites names are shown followed by (P) or (M), respectively.




Figure 4 Network of response related to diclofenac intervention, generated using MapEditor from GeneGo Inc. * indicates markers measured in the current study. Arrow pointing upward indicates increase in response to diclofenac treatment, arrow pointing downward indicates decrease in response to diclofenac treatment. PLA2: phospholipase A2; ANXA1: annexin A1; COX2: cyclooxygenase 2; 20-HETE: 20-hydroxyeicosatetraenoic acid; 5,6-EET: 5(6)-epoxyeicosatrienoic acid; 5,6-DHET: 5,6-dihydroxy-eicosatrienoic acid; PGG1: prostaglandin G1; PGE1: prostaglandin E1; PGES: prostaglandin E synthase; TCR: T cell receptor; MALT1: mucosa-associated lymphoid tissue lymphoma translocation protein 1; BNIP-XL: Protein prune homolog 2; LBC: A-kinase anchor protein 13 (AKAP13). IE: influence on expression, B: binding.

observed changes in PGE₂, TNF alpha and annexin A2 corroborate anti-inflammatory effects of the diclofenac treatment in the overweight subjects. Furthermore, more detailed biological network analysis allowed us to identify and visualize functionally related diclofenac responsive genes, proteins and metabolites. The markers in the network may each be sensitive markers of inflammatory modulation. However, it is important to note that a considerable number of diclofenac responsive genes are genes not previously associated with inflammation and genes with unknown function. Although these genes can therefore not be included in the biological network analysis, each of these could be potential interesting links for novel markers of inflammation associated with obesity.

Interestingly, the majority of the metabolites measured did not show a differential response between the diclofenac and the placebo group, with the exception of the metabolites of the oxylipids platform. However, in addition to measurements in fasting condition, the response of metabolites was also studied during an oral glucose tolerance test, performed at the beginning

and the end of the study, based on the idea that by challenging a system you can test its resilience. In the face of this metabolic challenge test, subtle diclofenac-responsive changes were detected, e.g. reduced plasma levels of uric acid and changes in levels of metabolites from the insulin regulated glutathione synthesis pathway. These findings are described in detail elsewhere [21].

Diclofenac intervention did not affect levels of the known inflammation markers CRP, sialic acid, VCAM or ICAM. Influences on plasma IL-6 could not be determined since levels were below the detection limit in the multiplex proteome analysis. In the placebo group, large within-subject variation of CRP was observed (Figure 2). This probably reflects the function of CRP as an acute phase protein and data suggested that a subset of subjects in the placebo group had unrecognized acute phase response underway at study day 0. In addition to the fluctuation over time, it should be noted that CRP levels also showed large between-subject variation (table 1, figure 2). It was evaluated whether this acute response of CRP was

reflected in the transcriptome, proteome and metabolome data sets by performing correlation analysis on CRP response and the gene, protein and oxylipid responses in all subjects. The network in additional file 5 illustrates biological connections between CRP and the most highly correlated genes and proteins (MetaCore™). The identified network of genes/proteins contains multiple nodes with roles in the acute phase response: complement 3 (C3), ferritin, PAI-1 [35]. Furthermore, the transcription factor STAT3, which can activate CRP transcription [12], has a central position in the network. The markers in this inflammation network may be more relevant as markers of fluctuations in acute inflammation than as markers of inflammatory modulation by pharmaceutical or nutritional intervention.

The panel of genes, proteins and metabolites modulated by diclofenac in this study appear to provide alternative measures of inflammatory status when associated with mild chronic conditions as observed in obesity. By using these markers to assess subject responsiveness prior to subject selection, the resulting reduction in variance is expected to increase the statistical power of studies designed to assess inflammatory intervention strategies in such chronic mild conditions. This increased power might then result in detection of changes in conventional inflammatory markers that were not detected in this study. It should be noted that larger subject groups could also contribute to increased power to detect changes in inflammatory markers. Furthermore, it should be noted that additional studies are needed to determine whether the markers identified here are specific for modulation of inflammation through inhibition of prostaglandin synthesis or if they are more general markers of inflammatory modulation. Ultimately, this study shows how the analysis and integration of a wide-range of parameters can lead to the selection of both known and new markers that respond to inflammatory modulation.

Conclusion

We report an array of new potential markers of inflammatory responsiveness to NSAID therapy in overweight subjects that include PBMC expression of ANXA1 and caspase 8, as well as plasma concentrations of 5,6-DHET. These findings constitute an advance in our ability to understand and quantify the status and modulation of inflammation in humans.

Additional file 1: Overview of plasma proteins. List of inflammation related plasma proteins measured in multiplex analysis. Click here for file
[http://www.biomedcentral.com/content/supplementary/1755-8794-3-5-S1.PDF]

Additional file 2: Changes in plasma oxylipids. Mean (\pm stdev) and median % change of plasma oxylipids selected by PLS-DA. Click here for file
[http://www.biomedcentral.com/content/supplementary/1755-8794-3-5-S2.PDF]

Additional file 3: Changes in plasma proteins. Mean (\pm stdev) and median % change of plasma proteins selected in PLS-DA. Click here for file
[http://www.biomedcentral.com/content/supplementary/1755-8794-3-5-S3.PDF]

Additional file 4: Enriched biological processes in selected set of genes. Enriched biological processes (based on Gene Ontology) in selected set of genes. Selected set of genes was analyzed in GenMAPP v2.0. Biological processes are ordered by Z-score. Click here for file
[http://www.biomedcentral.com/content/supplementary/1755-8794-3-5-S4.PDF]

Additional file 5: Network showing biological connections between genes and protein selected on highest correlation of expression change to CRP change. Network showing biological connections between genes and protein selected on highest correlation of expression change to CRP change (day 9 vs. day 0, $n = 18$). Network was generated using curated interactions in MetaCore v4.7 (GeneGo Inc., St. Joseph, MI, USA). Click here for file
[http://www.biomedcentral.com/content/supplementary/1755-8794-3-5-S5.PDF]

Acknowledgements

The authors express their gratitude to the volunteers that participated in the study, to the people from the Metabolic Research Unit and laboratories who assisted in the organization of the study and to Michèle van den Wijngaard and Jeffrey van Overeem for RNA isolation.

The authors are member of the European Nutrigenomics Organisation <http://www.nugo.org> and the Dutch Nutrigenomics Consortium.

Author details

¹TNO Quality of Life, PO Box 360, 3700 AJ Zeist, the Netherlands. ²Current address: CCMO, The Hague, the Netherlands. ³USDA, ARS, Western Human Nutrition Research Center, 430 West Health Sciences Dr, Davis, CA 95616, California, USA. ⁴Department of Nutrition, University of California, Davis, California, USA. ⁵Current address: Biosystems Data Analysis, Swammerdam Institute for Life Sciences, University of Amsterdam, Nieuwe Achtergracht 166, 1018 WV Amsterdam, the Netherlands.

Authors' contributions

MvE was responsible for generation and analysis of the microarray data, performed data integration and interpretation and drafted the manuscript; EV and SW were responsible for metabolomics measurements and metabolomics data analysis; TP and JN were responsible for oxylipids measurements; CR and AS performed the multivariate analysis. SW, CR, TP, JN, NP, AS, HH and BvO helped to draft the manuscript. TVV, NP, HH, JvdG and BvO designed the study. All authors read and approved the manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 16 July 2009

Accepted: 23 February 2010 Published: 23 February 2010

References

1. Berg AH, Scherer PE: Adipose tissue, inflammation, and cardiovascular disease. *Circulation Research* 2005, **96**:939-949.
2. Trayhurn P, Beattie JH: Physiological role of adipose tissue: White adipose tissue as an endocrine and secretory organ. *Proceedings of the Nutrition Society* 2001, **60**:329-339.

3. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK: **C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study.** *American Heart Journal* 2002, **144**:233-238.
4. Saadeddin SM, Habbab MA, Ferns GA: **Markers of inflammation and coronary artery disease.** *Medical Science Monitor* 2002, **8**(1).
5. Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AFH: **Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study.** *Diabetes* 2003, **52**:812-817.
6. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE: **Inflammatory Markers and Risk of Developing Type 2 Diabetes in Women.** *Diabetes* 2004, **53**:693-700.
7. Nesto RW: **Correlation between cardiovascular disease and diabetes mellitus: Current concepts.** *American Journal of Medicine* 2004, **8**:116.
8. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB: **Elevated C-reactive protein levels in overweight and obese adults.** *Journal of the American Medical Association* 1999, **282**:2131-2135.
9. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: **C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.** *N Engl J Med* 2004, **350**:1387-1397.
10. Laaksonen DE, Niskanen L, Nyyssönen K, Punnonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT: **C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men.** *Diabetologia* 2004, **47**:1402-1410.
11. Heinrich PC, Castell JV, Andus T: **Interleukin-6 and the acute phase response.** *Biochem J* 1990, **265**:621-636.
12. Zhang D, Sun M, Samols D, Kushner I: **STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6.** *J Biol Chem* 1996, **271**:9503-9509.
13. Lind L: **Circulating markers of inflammation and atherosclerosis.** *Atherosclerosis* 2003, **169**:203-214.
14. Funk CD: **Prostaglandins and leukotrienes: Advances in eicosanoid biology.** *Science* 2001, **294**:1871-1875.
15. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP: **Prostaglandins as modulators of immunity.** *Trends Immunol* 2002, **23**:144-150.
16. Hwang JS, Wu TL, Chou SC, Ho C, Chang PY, Tsao KC, Huang JY, Sun CF, Wu JT: **Development of multiple complications in type 2 diabetes is associated with the increase of multiple markers of chronic inflammation.** *Journal of Clinical Laboratory Analysis* 2008, **22**:6-13.
17. Browning LM, Krebs JD, Jebb SA: **Discrimination ratio analysis of inflammatory markers: implications for the study of inflammation in chronic disease.** *Metabolism* 2004, **53**:899-903.
18. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G: **Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study.** *Lancet* 1999, **353**:1649-1652.
19. Browning LM, Jebb SA, Mishra GD, Cooke JH, O'Connell MA, Crook MA, Krebs JD: **Elevated sialic acid, but not CRP, predicts features of the metabolic syndrome independently of BMI in women.** *International Journal of Obesity* 2004, **28**:1004-1010.
20. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, et al: **Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.** *JAMA* 2000, **284**:1247-1255.
21. Wopereis S, Rubingh CM, van Erk MJ, Verheij ER, van Vliet T, Cnubben NH, Smilde AK, Greef van der J, Van Ommen B, Hendriks HF: **Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes.** *PLoS ONE* 2009, **4**:e4525.
22. de Groot PJ, Reiff C, Mayer C, Muller M: **NuGO contributions to GenePattern.** *Genes Nutr* 2008, **3**:143-146.
23. Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR: **MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data.** *Genome Biol* 2003, **4**:R7.
24. Bijlsma S, Bobeldijk I, Verheij ER, Ramaker R, Kochhar S, Macdonald IA, Van Ommen B, Smilde AK: **Large-scale human metabolomics studies: A strategy for data (pre-) processing and validation.** *Analytical Chemistry* 2006, **78**:567-574.
25. Luria A, Weldon SM, Kabacnel AK, Ingraham RH, Matera D, Jiang H, Gill R, Morisseau C, Newman JW, Hammock BD: **Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice.** *J Biol Chem* 2007, **282**:2891-2898.
26. Barker M, Rayens W: **Partial least squares for discrimination.** *Journal of Chemometrics* 2003, **17**:166-173.
27. Martens H, Naes T: *Multivariate Calibration* Chichester, UK: John Wiley & Sons 1989.
28. Carroll MA, Balazy M, Margiotta P, Falck JR, McGiff JC: **Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins.** *Journal of Biological Chemistry* 1993, **268**:12260-12266.
29. Nusing RM, Schweer H, Fleming I, Zeldin DC, Wegmann M: **Epoxyeicosatrienoic acids affect electrolyte transport in renal tubular epithelial cells: Dependence on cyclooxygenase and cell polarity.** *American Journal of Physiology - Renal Physiology* 2007, **293**(1).
30. Stephenson AH, Sprague RS, Losapio JL, Lonigro AJ: **Differential effects of 5,6-EET on segmental pulmonary vasoactivity in the rabbit.** *American Journal of Physiology - Heart and Circulatory Physiology* 2003, **284**:H2153-61.
31. Lim LH, Pervaiz S: **Annexin 1: the new face of an old molecule.** *FASEB J* 2007, **21**:968-975.
32. Yucel-Lindberg T, Olsson T, Kawakami T: **Signal pathways involved in the regulation of prostaglandin E synthase-1 in human gingival fibroblasts.** *Cell Signal* 2006, **18**:2131-2142.
33. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB: **Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF- κ B activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation.** *Oncogene* 2004, **23**:9247-9258.
34. Poligone B, Baldwin AS: **Positive and negative regulation of NF- κ B by COX-2. Roles of different prostaglandins.** *Journal of Biological Chemistry* 2001, **276**:38658-38664.
35. Gabay C, Kushner I: **Acute-phase proteins and other systemic responses to inflammation.** *N Engl J Med* 1999, **340**:448-454.

Pre-publication history

The pre-publication history for this paper can be accessed here: <http://www.biomedcentral.com/1755-8794/3/5/prepub>

doi:10.1186/1755-8794-3-5

Cite this article as: van Erk et al.: Insight in modulation of inflammation in response to diclofenac intervention: a human intervention study. *BMC Medical Genomics* 2010 **3**:5.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

